newsfilter
← Latest News
GlobeNewswire·

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

NRXP
  • NRx Pharmaceuticals, Inc. announced a corporate update conference call scheduled for Tuesday, December 2, 2025, at 9:00am ET.
  • The call will cover recent clinical, regulatory, & operational developments.
  • A live webcast is available at ir.nrxpharma.com/events, with telephone access via 1-800-717-1738 (domestic) or 1-646-307-1865 (international).
  • NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on Neuroplastic Therapies for CNS disorders including suicidal depression, PTSD, anxiety, & Autism.
  • The company combines drug development with HOPE Therapeutics, a network offering medication management, Transcranial Magnetic Stimulation, & Hyperbaric Oxygen Therapy.
  • NRX-100 (preservative-free intravenous ketamine) received Fast Track Designation for suicidal ideation in depression, including bipolar depression.
  • NRX-101 (oral D-cycloserine/lurasidone) received Breakthrough Therapy Designation for suicidal bipolar depression.
  • An Abbreviated New Drug Application for the preservative-free ketamine formulation has been filed, with a launch anticipated for July 2026.
  • HOPE Therapeutics, a subsidiary, is building an interventional psychiatry clinic network & is the first in Florida to offer the AMPA One Day (ONE-D) treatment for treatment-resistant depression.
  • The announcement includes standard forward-looking statement disclaimers regarding future events, risks, & uncertainties.
  • Contact information provided includes Matthew Duffy (Co-CEO, HOPE Therapeutics) & Brian Korb (Chief Business Officer, NRx Pharmaceuticals).